½ÃÀ庸°í¼­
»óǰÄÚµå
1673881

Ç×µ¶¼Ò ½ÃÀå : Ç×µ¶¼Ò À¯Çüº°, Á¦Ç° À¯Çüº°, ÃÖÁ¾»ç¿ëÀÚº°, Áö¿ªº°

Anti Venom Market, By Anti-venom Type, By Product Type, By End User, By Geography

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Coherent Market Insights | ÆäÀÌÁö Á¤º¸: ¿µ¹® | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

Ç×µ¶¼Ò ¼¼°è ½ÃÀåÀº 2025³â¿¡ 13¾ï 8,200¸¸ ´Þ·¯, 2032³â¿¡´Â 24¾ï 9,570¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç 2025³âºÎÅÍ 2032³â±îÁö ¿¬Æò±Õ 8.8%ÀÇ ¼ºÀå·üÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

º¸°í ¹üÀ§ º¸°í¼­ »ó¼¼ ³»¿ë
±âÁØ ¿¬µµ 2024³â 2025³â ½ÃÀå ±Ô¸ð 13¾ï 8,200¸¸ ´Þ·¯
½ÇÀû µ¥ÀÌÅÍ 2020-2024³â ¿¹Ãø ±â°£ 2025-2032³â
¿¹Ãø ±â°£(2025-2032³â) CAGR 8.80% 2032³â °¡Ä¡ ¿¹Ãø 24¾ï 9,570¸¸ ´Þ·¯
±×¸². 2025³â Ç×µ¶¼Ò ½ÃÀå Áö¿ªº° Á¡À¯À²(%)
Anti Venom Market-IMG1

¼¼°è Ç×µ¶¼Ò ½ÃÀåÀÇ ¼ºÀåÀº Àü ¼¼°è ¿­´ë ¹× ¾Æ¿­´ë Áö¿ªÀÇ ¹ì°ú Àü°¥¿¡ ÀÇÇÑ ¹°¸²°ú Àü°¥¿¡ ÀÇÇÑ ½îÀÓ ¹ß»ý·ü Áõ°¡¿¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. ¸Å³â 500¸¸ ¸í ÀÌ»óÀÌ ¹ì¿¡ ¹°¸®°í ±× Áß ¾à 270¸¸ °ÇÀÌ Áßµ¶µÇ¾î ¾à 10¸¸ ¸íÀÌ »ç¸ÁÇϰí ÀÖ½À´Ï´Ù. È¿°úÀûÀÎ ±¸ÃæÁ¦°¡ Ãâ½ÃµÇ¸é¼­ ¸¹Àº ±¹°¡¿¡¼­ ¹ì¿¡ ¹°¸° ÇÇÇØÀÚÀÇ »ýÁ¸À²°ú ȸº¹·üÀÌ Çâ»óµÇ¾î ±¸ÃæÁ¦¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ÁÖ¿ä Á¦Á¶¾÷üµéÀº ÃֽŠ¸é¿ªÇÐÀû ¹× »ýÈ­ÇÐÀû ¹æ¹ýÀ» ÀÌ¿ëÇÑ »ý»ê ±â¼ú °³ÇõÀ» ÅëÇØ »õ·Î¿î Ç׺£³ðÀ» °³¹ßÇϱâ À§ÇØ ³ë·ÂÇϰí ÀÖ½À´Ï´Ù. Àû½Ã Ä¡·á¿Í Ç׺£³ðÀÇ °¡¿ë¼º¿¡ ´ëÇÑ ÀÎ½Ä Á¦°í¸¦ À§ÇÑ ÅõÀÚ Áõ°¡µµ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ ¼ö ÀÖ½À´Ï´Ù.

½ÃÀå ¿ªÇÐ

¼¼°è Ç×µ¶¼Ò ½ÃÀåÀÇ ¼ºÀåÀº ÁÖ·Î Àü ¼¼°è ¹ì°ú Àü°¥¿¡ ¹°¸° ¹ß»ý·ü Áõ°¡¿¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. ¼¼°èº¸°Ç±â±¸(WHO)¿¡ µû¸£¸é ¸Å³â ¾à 540¸¸ ¸íÀÌ ¹ì¿¡ ¹°¸®°í ¾à 270¸¸ ¸íÀÌ ½î¿© ¾à 13¸¸ 7000¸íÀÌ »ç¸ÁÇÕ´Ï´Ù. ½ÃÀå °ü°èÀÚ¿Í Á¤ºÎ´Â ³óÃÌ Áö¿ª ÁֹεéÀ» ±³À°Çϰí, ÀÇ·á ½Ã¼³¿¡ ´ëÇÑ Á¢±Ù¼ºÀ» °³¼±Çϰí, ¿Üµý Áö¿ª¿¡¼­ Ç×µ¶¼ÒÀÇ °¡¿ë¼ºÀ» º¸ÀåÇϱâ À§ÇØ ÅõÀÚ¸¦ ´Ã¸®°í ÀÖ½À´Ï´Ù. ±×·¯³ª Ç׺£³ðÀº ³ôÀº ºñ¿ë°ú ªÀº ÀúÀå ±â°£, º¸°ü ¹× ¿î¼Û¿¡ ´ëÇÑ Á¦¾à°ú °ü¸®·Î ÀÎÇØ º¸±Þ¿¡ ÇѰ谡 ÀÖ½À´Ï´Ù. ÀÎ½Ä ºÎÁ·, ÀüÅëÀû ¹ÏÀ½, Áö¸®Àû À庮À¸·Î ÀÎÇØ °³¹ßµµ»ó±¹ ÇÇÇØÀÚµéÀÌ Àû½Ã¿¡ Ä¡·á¸¦ ¹ÞÀ» ¼ö ÀÖ´Â ±âȸ¸¦ Á¦ÇÑÇϰí ÀÖ½À´Ï´Ù. Çõ½ÅÀûÀ̰í È¿°úÀûÀ̸ç ÇÕ¸®ÀûÀÎ °¡°ÝÀÇ Ç׺£³ðÁ¦¸¦ ¿¬±¸ÇÏ°í »ý»êÇÏ´Â ½ÃÀå Âü¿©ÀÚµéÀº ½ÃÀå ¼ºÀåÀÇ ±âȸ¸¦ Á¦°øÇÒ ¼ö ÀÖ½À´Ï´Ù.

º» Á¶»çÀÇ ÁÖ¿ä Æ¯Â¡

  • ¼¼°èÀÇ Ç×µ¶¼Ò ½ÃÀåÀ» »ó¼¼ÇÏ°Ô ºÐ¼®Çϰí, 2022³âÀ» ±âÁØ ¿¬µµ·Î ÇÏ¿© ¿¹Ãø ±â°£(2025-2032³â) ½ÃÀå ±Ô¸ð¿Í ¿¬Æò±Õ ¼ºÀå·ü(CAGR)À» Á¶»çÇÏ¿© ÀüÇØµå¸³´Ï´Ù.
  • ¶ÇÇÑ, ´Ù¾çÇÑ ºÎ¹®¿¡ °ÉÄ£ ÀáÀçÀû ¼öÀÍ ±âȸ¸¦ ¹àÈ÷°í, ÀÌ ½ÃÀåÀÇ ¸Å·ÂÀûÀÎ ÅõÀÚ Á¦¾È ¸ÅÆ®¸¯½º¸¦ ¼³¸íÇÕ´Ï´Ù.
  • ¶ÇÇÑ ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ, ¾ïÁ¦¿äÀÎ, ±âȸ, ½ÅÁ¦Ç° Ãâ½Ã ¹× ½ÂÀÎ, ½ÃÀå µ¿Çâ, Áö¿ªº° Àü¸Á, ÁÖ¿ä ±â¾÷ÀÇ °æÀï Àü·« µî¿¡ ´ëÇÑ Áß¿äÇÑ °íÂûÀ» Á¦°øÇÕ´Ï´Ù.
  • ÀÌ º¸°í¼­´Â ±â¾÷ ÇÏÀ̶óÀÌÆ®, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÁÖ¿ä ÇÏÀ̶óÀÌÆ®, À繫 ¼º°ú, Àü·« µîÀÇ ¸Å°³ º¯¼ö¸¦ ±â¹ÝÀ¸·Î ¼¼°è Ç×µ¶¼Ò ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷À» ÇÁ·ÎÆÄÀϸµÇÕ´Ï´Ù.
  • ÀÌ º¸°í¼­ÀÇ ÅëÂû·ÂÀ» ÅëÇØ ¸¶ÄÉÆÃ ´ã´çÀÚ¿Í ±â¾÷ °æ¿µÁøÀº ÇâÈÄ Á¦Ç° Ãâ½Ã, À¯Çü ¾÷±×·¹À̵å, ½ÃÀå È®´ë, ¸¶ÄÉÆÃ Àü¼ú¿¡ ´ëÇÑ Á¤º¸¿¡ ÀÔ°¢ÇÑ ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖ½À´Ï´Ù.
  • ¼¼°è Ç×µ¶¼Ò ½ÃÀå º¸°í¼­´Â ÅõÀÚÀÚ, °ø±Þ¾÷ü, Á¦Ç° Á¦Á¶¾÷ü, À¯Åë¾÷ü, ½Å±Ô ½ÃÀå ÁøÃâ±â¾÷, À繫 ºÐ¼®°¡ µî ¾÷°èÀÇ ´Ù¾çÇÑ ÀÌÇØ°ü°èÀÚ¸¦ ´ë»óÀ¸·Î ÇÕ´Ï´Ù.
  • ÀÌÇØ°ü°èÀÚµéÀº ¼¼°è Ç×µ¶¼Ò ½ÃÀå ºÐ¼®¿¡ »ç¿ëµÇ´Â ´Ù¾çÇÑ Àü·« ¸ÅÆ®¸¯½º¸¦ ÅëÇØ ÀÇ»ç°áÁ¤À» ¿ëÀÌÇÏ°Ô ÇÒ ¼ö ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¸ñÀû°ú ÀüÁ¦Á¶°Ç

  • Á¶»ç ¸ñÀû
  • ÀüÁ¦Á¶°Ç
  • ¾à¾î

Á¦2Àå ½ÃÀå Àü¸Á

  • º¸°í¼­ ¼³¸í
    • ½ÃÀå Á¤ÀÇ¿Í ¹üÀ§
  • ÁÖ¿ä ¿ä¾à
  • Coherent Opportunity Map(COM)

Á¦3Àå ½ÃÀå ¿ªÇÐ, ±ÔÁ¦, µ¿Ç⠺м®

  • ½ÃÀå ¿ªÇÐ
    • ¼ºÀå ÃËÁø¿äÀÎ
    • ¼ºÀå ¾ïÁ¦¿äÀÎ
    • ±âȸ
  • ¿µÇ⠺м®
  • ½ÃÀå µ¿Çâ
  • ÁÖ¿ä ¹ßÀü
  • ±ÔÁ¦ ½Ã³ª¸®¿À
  • Àμö¿Í Á¦ÈÞ ½Ã³ª¸®¿À
  • ÀÚ±ÝÁ¶´Þ°ú ÅõÀÚ
  • PEST ºÐ¼®
  • PorterÀÇ Five Forces ºÐ¼®

Á¦4Àå ¼¼°èÀÇ Ç×µ¶¼Ò ½ÃÀå - Äڷγª¹ÙÀÌ·¯½º(COVID-19) ÆÒµ¥¹ÍÀÇ ¿µÇâ

  • ÀüüÀûÀÎ ¿µÇâ
  • Á¤ºÎ ÀÌ´Ï¼ÅÆ¼ºê
  • ½ÃÀå¿¡ ´ëÇÑ COVID-19ÀÇ ¿µÇâ

Á¦5Àå ¼¼°èÀÇ Ç×µ¶¼Ò ½ÃÀå, Ç×µ¶¼Ò À¯Çüº°, 2020³â-2032³â

  • ´Ù°¡
  • ´Ü°¡

Á¦6Àå ¼¼°èÀÇ Ç×µ¶¼Ò ½ÃÀå, Á¦Ç° À¯Çüº°, 2020³â-2032³â

  • ¹ì Ç×µ¶¼Ò
  • Àü°¥ Ç×µ¶¼Ò
  • °Å¹Ì Ç×µ¶¼Ò
  • ±âŸ

Á¦7Àå ¼¼°èÀÇ Ç×µ¶¼Ò ½ÃÀå, ÃÖÁ¾»ç¿ëÀÚº°, 2020³â-2032³â

  • º´¿ø ¹× Ŭ¸®´Ð
  • ¿Ü·¡¼ö¼ú¼¾ÅÍ(ASC)
  • ¿¬±¸±â°ü
  • ±âŸ

Á¦8Àå ¼¼°èÀÇ Ç×µ¶¼Ò ½ÃÀå, Áö¿ªº°, 2020³â-2032³â

  • ºÏ¹Ì
  • ¶óƾ¾Æ¸Þ¸®Ä«
  • À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
  • Áßµ¿
  • ¾ÆÇÁ¸®Ä«

Á¦9Àå °æÀï ±¸µµ

  • ±â¾÷ °³¿ä
    • Pfizer, Inc.
    • Merck &Co., Inc.
    • Sanofi Pasteur
    • 4CSL Limited
    • Haffkine Bio-Pharmaceutical Corporation Ltd.
    • Instituto Bioclon SA de CV
    • Rare Disease Therapeutics, Inc.
    • Vins Bioproducts Limited
    • Bharat Serums and Vaccines Limited
    • Serum Institute of India Pvt. Ltd.
    • Incepta Pharmaceuticals Ltd.
    • MicroPharm Limited
    • Laboratorios Silanes SA
    • BTG plc
    • Vacsera
    • Indian Immunologicals Limited
    • AfrIPI(African Institute of Biomedical Science and Technology)

Á¦10Àå ¾Ö³Î¸®½ºÆ® Ãßõ »çÇ×

  • ±âȸ
  • ¾Ö³Î¸®½ºÆ®ÀÇ °ßÇØ
  • Coherent Opportunity Map

Á¦11Àå Âü°í ¹®Çå°ú Á¶»ç ¹æ¹ý

  • Âü°í ¹®Çå
  • Á¶»ç ¹æ¹ý
LSH 25.04.14

Global Anti Venom Market is estimated to be valued at USD 1,382.0 Mn in 2025 and is expected to reach USD 2,495.7 Mn by 2032, growing at a compound annual growth rate (CAGR) of 8.8% from 2025 to 2032.

Report Coverage Report Details
Base Year: 2024 Market Size in 2025: USD 1,382.0 Mn
Historical Data for: 2020 To 2024 Forecast Period: 2025 To 2032
Forecast Period 2025 to 2032 CAGR: 8.80% 2032 Value Projection: USD 2,495.7 Mn
Figure. Anti Venom Market Share (%), By Region 2025
Anti Venom Market - IMG1

Global anti venom market growth is driven by rising incidence of snake bites and scorpion stings across tropical and sub-tropical regions of the world. Each year over 5 million people are bitten by snakes, out of which, around 2.7 million cases result in envenoming and around 100,000 deaths. There has been rising demand for anti-venom as the availability of effective anti-venoms has improved survival and recovery rates for victims of snake bites in many countries. Leading manufacturers are engaging in development of novel anti-venoms through reforms in production techniques using modern immunological and biochemical methods. Rising investments towards building awareness about timely treatment and availability of anti-venoms can also drive the market growth.

Market Dynamics:

Global anti venom market growth is primarily driven by increasing incidence of snake bites and scorpion stings globally. According to the World Health Organization, around 5.4 million people suffer from snake bites each year and about 2.7 million are envenomed with around 137,000 deaths. Rising investments by market players and governments towards educating rural populations, improving access to healthcare facilities and ensuring availability of anti-venoms across remote areas can offer lucrative opportunities. However, high costs of anti-venoms, short shelf-life requiring constrained and controlled storage and transportation can limit its widespread adoption. Lack of awareness, traditional beliefs and geographical barriers restrict timely treatment seeking for victims in developing nations. Market players involved in research and production of innovative, more effective and affordable anti-venoms can offer market growth opportunities.

Key features of the study:

  • This report provides in-depth analysis of the global anti venom market, and provides market size (USD Million) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2022 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global anti venom market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
  • Key companies covered as a part of this study include Bharat Serums & Vaccines, Haffkine Bio-Pharmaceutical Corporation, Vins Bioproducts, Bharat Biotech, and Serum Institute of India
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • Global anti venom market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global anti venom market

Detailed Segmentation-

  • By Anti-venom Type
    • Polyvalent
    • Monovalent
  • By Product Type
    • Snake Antivenom
    • Scorpion Anti-venom
    • Spider Anti-venom
    • Others
  • By End User
    • Hospitals & clinics
    • Ambulatory Surgical Centers
    • Research Institutes
    • Others
  • By Region
    • North America
    • Europe
    • Asia Pacific
    • Latin America
    • Middle East
    • Africa
  • Company Profiles:
    • Pfizer, Inc.
    • Merck & Co., Inc.
    • Sanofi Pasteur
    • 4CSL Limited
    • Haffkine Bio-Pharmaceutical Corporation Ltd.
    • Instituto Bioclon S.A. de C.V.
    • Rare Disease Therapeutics, Inc.
    • Vins Bioproducts Limited
    • Bharat Serums and Vaccines Limited
    • Serum Institute of India Pvt. Ltd.
    • Incepta Pharmaceuticals Ltd.
    • MicroPharm Limited
    • Laboratorios Silanes S.A.
    • BTG plc
    • Vacsera
    • Indian Immunologicals Limited
    • AfrIPI (African Institute of Biomedical Science and Technology)

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snapshot, By Anti-venom Type
    • Market Snapshot, By Product Type
    • Market Snapshot, By End User
    • Market Snapshot, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Opportunities
  • Impact Analysis
  • Market Trends
  • Key Developments
  • Regulatory Scenario
  • Acquisitions and Partnerships Scenario
  • Funding and Investments
  • PEST Analysis
  • Porter's Analysis

4. Global Anti Venom Market - Impact of Coronavirus (COVID-19) Pandemic

  • Overall Impact
  • Government Initiatives
  • COVID-19 Impact on the Market

5. Global Anti Venom Market, By Anti-venom Type, 2020 - 2032, (USD Mn)

  • Overview
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2020 - 2032
    • Segment Trends
  • Polyvalent
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
  • Monovalent
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)

6. Global Anti Venom Market, By Product Type, 2020 - 2032, (USD Mn)

  • Overview
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2020 - 2032
    • Segment Trends
  • Snake Antivenom
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
  • Scorpion Anti-venom
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
  • Spider Anti-venom
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
  • Others
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)

7. Global Anti Venom Market, By End User, 2020 - 2032, (USD Mn)

  • Overview
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2020 - 2032
    • Segment Trends
  • Hospitals & Clinics
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
  • Ambulatory Surgical Centers
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
  • Research Institutes
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
  • Others
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)

8. Global Anti Venom Market, By Region, 2020 - 2032, (USD Mn)

  • Introduction
    • Market Share Analysis, By Region, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, For Region, 2020-2032
    • Regional Trends
  • North America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Anti-venom Type, 2020 - 2032, (USD Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2020 - 2032, (USD Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2020 - 2032, (USD Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Mn)
      • U.S.
      • Canada
  • Latin America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Anti-venom Type, 2020 - 2032, (USD Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2020 - 2032, (USD Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2020 - 2032, (USD Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Mn)
      • Brazil
      • Mexico
      • Argentina
      • Rest of Latin America
  • Europe
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Anti-venom Type, 2020 - 2032, (USD Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2020 - 2032, (USD Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2020 - 2032, (USD Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Mn)
      • U.K.
      • Germany
      • Italy
      • France
      • Spain
      • Russia
      • Rest of Europe
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Anti-venom Type, 2020 - 2032, (USD Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2020 - 2032, (USD Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2020 - 2032, (USD Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Mn)
      • China
      • India
      • Japan
      • ASEAN
      • Australia
      • South Korea
      • Rest of Asia Pacific
  • Middle East
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Anti-venom Type, 2020 - 2032, (USD Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2020 - 2032, (USD Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2020 - 2032, (USD Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Mn)
      • GCC Countries
      • Israel
      • Rest of Middle East
  • Africa
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Anti-venom Type, 2020 - 2032, (USD Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2020 - 2032, (USD Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2020 - 2032, (USD Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2020 - 2032, (USD Mn)
      • North Africa
      • Central Africa
      • South Africa

9. Competitive Landscape

  • Company Profiles
    • Pfizer, Inc.
      • Company Highlights
      • Anti-venom Type Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Merck & Co., Inc.
      • Company Highlights
      • Anti-venom Type Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Sanofi Pasteur
      • Company Highlights
      • Anti-venom Type Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • 4CSL Limited
      • Company Highlights
      • Anti-venom Type Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Haffkine Bio-Pharmaceutical Corporation Ltd.
      • Company Highlights
      • Anti-venom Type Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Instituto Bioclon S.A. de C.V.
      • Company Highlights
      • Anti-venom Type Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Rare Disease Therapeutics, Inc.
      • Company Highlights
      • Anti-venom Type Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Vins Bioproducts Limited
      • Company Highlights
      • Anti-venom Type Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Bharat Serums and Vaccines Limited
      • Company Highlights
      • Anti-venom Type Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Serum Institute of India Pvt. Ltd.
    • Incepta Pharmaceuticals Ltd.
    • MicroPharm Limited
    • Laboratorios Silanes S.A.
    • BTG plc
    • Vacsera
    • Indian Immunologicals Limited
    • AfrIPI (African Institute of Biomedical Science and Technology)

10. Analyst Recommendations

  • Wheel of Fortune
  • Analyst View
  • Coherent Opportunity Map

11. References and Research Methodology

  • References
  • Research Methodology
  • About us and Sales Contact
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦